Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO

Persistent Pyelonephritis and Renal Abscess due to Mycoplasma hominis in an Immunocompromised Patient: A Case Report

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis

Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study

Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial

Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses

Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy